Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...
Cardiovascular imaging, which continues to evolve alongside interventions and other technologies, made notable strides in the ...
AHA 2023 Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate' A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback